Abstract
High-affinity extrasynaptic gamma-aminobutyric acid A (GABAA) receptors are tonically activated by low and consistent levels of ambient GABA, mediating chronic inhibition against neuronal excitability (tonic inhibition) and the modulation of neural development. Synaptic (phasic) inhibition is spatially and temporally precise compared with tonic inhibition, which provides blunt yet strong integral inhibitory force by shunting electrical signaling. Although effects of acute modification of tonic inhibition are known, its pathophysiological significance remains unclear because homeostatic regulation of neuronal excitability can compensate for long-term deficit of extrasynaptic GABAA receptor activation. Nevertheless, tonic inhibition is of great interest for its pathophysiological involvement in central nervous system (CNS) diseases and thus as a therapeutic target. Together with the development of experimental models for various pathological states, recent evidence demonstrates such pathological involvements of tonic inhibition in neuronal dysfunction. This review focuses on the recent progress of tonic activation of GABAA conductance on the development and pathology of the CNS. Findings indicate that neuronal function in various brain regions are exacerbated with a gain or loss of function of tonic inhibition by GABA spillover. Disturbance of tonic GABAA conductance mediated by non-synaptic ambient GABA may result in brain mal-development. Therefore, various pathological states (epilepsy, motor dysfunctions, psychiatric disorders, and neurodevelopmental disorders) may be partly attributable to abnormal tonic GABAA conductances. Thus, the tone of tonic conductance and level of ambient GABA may be precisely tuned to maintain the regular function and development of the CNS. Therefore, receptor expression and factors for regulating the ambient GABA concentration are highlighted to gain a deeper understanding of pathology and therapeutic strategy for CNS diseases.
INTRODUCTION
Neurotransmission comprises both excitatory and inhibitory signals. Therefore, understanding the mechanisms underlying the imbalance of these signals that are found in pathologies of the central nervous systems (CNSs) are vital in pursuing specific therapeutic strategies. In inhibitory neurotransmitter systems, gamma-aminobutyric acid (GABA) A receptor (GABAA)-mediated synaptic transmission is particularly important because its fast, ligand-gated inhibitory conductance allows fine homeostatic tuning of excitation-inhibition balance (see review ; Olsen and Sieghart, 2008).
Accumulating evidence has revealed that the function and distribution of the GABAA receptor are remarkably diverse because of their subunit assembly. Some GABAA receptor isoforms have been shown to be expressed outside synapses, and tonically activated by low concentrations of GABA (i.e., tonic inhibition) existing in the extrasynaptic space (Mody and Pearce, 2004; ). Although the proportion of GABAA receptor subtypes mediating tonic inhibition is estimated to be of minor abundance as compared with that mediating synaptic inhibition (Mohler et al., 2002), this effect nevertheless provides strong inhibitory force by shunting the electrical signal transmission. With increased knowledge about its functional significance, an alteration in tonic inhibition has received great attention as a mechanism underlying the pathophysiology of various CNS disorders. Its distinct properties and pharmacology may thus provide new therapeutic strategies for overcoming limitations of conventional GABAA receptor modulators. Thus far, deregulation of tonic inhibition has been shown to be a mechanism responsible for underlying a variety of CNS pathologies, including epilepsy, neurodevelopmental disorders, cognitive dysfunctions, and psychiatric disorders (see review, ; ).
In addition to tonic inhibition induced by GABA generated by synaptic spillover, another form of tonic conductance occurs before synaptic formation. This tonic conductance is depolarizing because the intracellular chloride (Cl-) concentration is high in immature neurons due to the balance of Cl- transporters (Owens et al., 1996; Yamada et al., 2004; for review, see ). The release of GABA in the milieu occurs via non-vesicular mechanisms (; Manent et al., 2005; for review, see Owens and Kriegstein, 2002). This tonic GABAA receptor-mediated conductance is considered to be involved in a variety of developmental events, such as neurogenesis (; ; ), migration (,,,; ; ; ; ; ; ; ) and synaptogenesis (Nakanishi et al., 2007; Wang and Kriegstein, 2008). Based on these findings, perturbation of tonic depolarization could also result in brain mal-development.
In this review, we provide an overview on the advancement in knowledge about the role of dysregulation of tonic inhibition in the pathophysiology of various CNS diseases (with the exception of epilepsy, which will be reviewed independently in this issue), and its involvement in their therapeutic strategies. Furthermore, we review the latest findings of tonic depolarization underlying brain mal-development (with the exception of the hippocampus, which will be reviewed independently in this issue).
RECEPTOR COMPOSITION AND DISTRIBUTION OF TONIC INHIBITION
Gamma-aminobutyric acid A receptors are assembled from a family of 19 homologous subunit gene products (six α subunits, three β subunits, three γ subunits, three ρ subunits, and one each of the ε, δ, θ, and π subunits) and form mostly hetero-oligomeric pentamers (for review, see Olsen and Sieghart, 2008). Most GABAA receptor subtypes are formed from two copies of a single α, two copies of a single β, and one copy of another subunit (γ, δ, or ε). Each subunit combination has a distinct distribution pattern in terms of subcellular domains. The δ subunit, generally partnered with the α4 (forebrain predominant) and α6 (cerebellum predominant) subunits, are shown to be exclusively localized in extrasynaptic membranes in various neuronal cells, including cerebellar granule cells (CGCs), dentate gyrus granule cells, neocortical layer 2/3 pyramidal cells (Nusser et al., 1998; Nusser and Mody, 2002; Wei et al., 2003), interneurons in the neocortex and hippocampus (Semyanov et al., 2003; ), thalamic relay neurons (), medium spiny neurons of the striatum (), and dorsal horn spinal neurons (). The δ subunit-containing GABAA (δ-GABAA) receptor shows high affinity and slow desensitization to GABA (Saxena and MacDonald, 1996), which allows tonic activation in response to low concentration of ambient GABA in extrasynaptic space (though see ).
The α5 subunit-containing GABAA receptors, which presumably do not include the δ subunit, are also expressed in extrasynaptic membranes. The α5 subunit is predominantly detected in hippocampal pyramidal neurons (Sperk et al., 1997), showing higher GABA sensitivity compared with α1 GABAA receptors, which allows tonic inhibition in hippocampal pyramidal neurons (; ). The α1 and α5 subunit-mediated tonic inhibition is also shown in cortical principal neurons in layer 2/3 and layer 5, respectively (Yamada et al., 2007). In line with the predominant distribution of extrasynaptic α5 subunit-containing GABAA receptors (; ; ), perisynaptic α5 subunits also mediate the GABA spillover component of slow phasic inhibitory currents (Prenosil et al., 2006). The contribution of such a slow inhibitory synapse transmission to the signal computation may be a future issue to explore with further studies.
The other assemblies (e.g., α1γ2 subunit-containing receptor), which mainly mediate synaptic inhibition, also exist in the extrasynaptic membrane () and can contribute to tonic inhibition because their specific agonist, zolpidem, amplifies the tonic currents (Semyanov et al., 2003; Yamada et al., 2007). High affinity αβ subunit-containing GABAA receptors have also been shown to mediate tonic inhibition in rat hippocampal pyramidal neurons (Mortensen and Smart, 2006). Nevertheless, it is now clear that the GABAA receptor subtypes having the δ or α5 subunit are the dominant forms which are responsible for mediating tonic inhibition in the mammalian brain, including humans (Scimemi et al., 2006).
REGULATION OF TONIC INHIBITION
After the finding of tonic inhibition in the mature brain (), its functional significance for regulating network excitability was subsequently revealed. In CGCs, blocking tonic inhibition decreases membrane shunting () and increases information flow from granule cells to Purkinje cells (). In thalamic relay neurons or hippocampal interneurons, baseline membrane potentials and network oscillation are modulated (; Song et al., 2011). Deregulation of tonic inhibition caused by a lack of synaptic plasticity-associated proteins has been shown in several mice models of neurological disorders (; Olmos-Serrano et al., 2010; ). However, the pathophysiological significance of long-term modification of extrasynaptic GABAA receptor activation can be masked by compensatory mechanisms (; Wisden et al., 2002). Some adaptive regulation responses could be attributed to the modification of GABAA receptor trafficking and/or clustering on the membrane surface (Saliba et al., 2012; see review ).
Progress in the development of pharmacological agents that predominantly modulate extrasynaptic GABAA receptors (summarized in Table 1) has contributed to the uncovering of the pathological significance of dysregulated tonic inhibition. Consequently, large efforts have been made to use these agents for clinical use. The negative allosteric modulator of the α5 GABAA receptor, α5IA, has recently been shown to improve ethanol-induced impaired performance in healthy subjects (Nutt et al., 2007). However, its use in a clinical trial was stopped due to renal toxicity (). Another negative allosteric modulator of the α5 subunit, RO4938581, is presently under a phase 1 clinical trial for Down syndrome (the study is sponsored by Roche, and its outcomes have been made publicly available). The selective orthosteric agonist of the δ-GABAA receptor, 4,5,6,7-tetrahydroisoxazolo(5,4-c)pyridin-3-ol (THIP, or also known as gaboxadol) was used as an hypnotic drug, reaching a phase 3 trial before its cessation because of side-effects, such as hallucination and disorientation (the study is sponsored by Merck, and its outcomes have been made publicly available). However, THIP has been recently shown to be effective against behavioral and motor dysfunction in mouse models of autism spectrum disorders (Olmos-Serrano et al., 2011; ). Therefore, further cumulative evidence may hopefully renew an interest in using THIP for these diseases, which have no effective therapeutic strategies.
Table 1
| δ-Subunit selective | ||
|---|---|---|
| THIP (4,5,6,7-tetrahydroisoxazolo (5,4-c)pyridin-3-ol; gaboxadol) | Selective orthosteric agonist of δ-GABAA receptor, a restricted analog of muscimol | |
| AA29504 | Positive allosteric modulator of δ-GABAA receptor, analog of Kv7 channel opener, retigabine | , Vardya et al. (2012) |
| DS2 | Positive allosteric modulator of δ-GABAA receptor, poor blood–brain barrier permeability | Wafford et al. (2009), |
| THDOC | Positive allosteric modulat,or of δ-GABAA receptor, an endogenous neurosteroid | |
| α5-Subunit selective | ||
| RO4938581 | Negative allosteric modulator of α5-GABAA receptor, now entering to phase1 trial for Down syndrome | |
| α5IA | Negative allosteric modulator of α5-GABAA receptor, development has stopped due to renal toxicity | |
| MRK-016 | Negative allosteric modulator of α5-GABAA receptor, more potent than α5IA | |
| L-655,708 | Negative allosteric modulator of α5-GABAA receptor | |
| SH-053-20F-R-CH3 | Positive allosteric modulator of α5-GABAA receptor | |
Selective modulators for extrasynaptic GABAA receptor.
Because extrasynaptic GABAA receptors are activated by ambient GABA in the extrasynaptic space, regulation of ambient GABA concentrations must therefore be an important factor for determining the degree of tonic inhibition. The concentration of ambient GABA has been estimated to be very low, less than 300 nM in both in vivo () and in vitro (Wu et al., 2003; Santhakumar et al., 2006) conditions. A considerable part of ambient GABA may be derived from spillover from the synaptic cleft (). Thus, presynaptic functions, such as GABA synthesis and GABA release, should also regulate tonic GABA conductance. To date, reverse mode operation of GABA transporters (Wu et al., 2003; ) and GABA release via bestrophin1 anion channel () have been proposed as mechanisms underlying the non-vesicular release of GABA, both of which are currently under debate (; ).
Regardless of the source of ambient GABA, GABA transporters play a pivotal role in regulating tonic inhibition. In the rat hippocampus, presynaptically located GABA transporter 1 (GAT1) and astrocytic GAT3 (corresponding to GAT4 in mice) synergistically modulate the ambient concentration of GABA via its uptake from the extrasynaptic space (; ; Song et al., 2013). In vivo analysis has shown that neuronal GAT1 plays a predominant role under resting conditions and that the uptake of GABA by astrocytic GAT3 occurs during membrane depolarization (). In general, GAT1 and GAT3 is expressed in presynaptic neurons and astrocytes, respectively. However, this expression pattern is not consistent throughout the brain regions. For example, thalamic GAT1 and GAT3 are exclusively expressed in astrocytes, but not in presynaptic neurons (), and thus the regulatory mechanisms for ambient GABA in the brain can differ depending on the region. Recently, compromised function of glial GATs (associated with increased tonic inhibition), has been shown to underlie the pathophysiology of absence epilepsy () and prevent recovery after stroke (). Insufficient () or excessive () amounts of GAT1 can cause cerebellar dysfunction, at least in part, to deregulation of tonic inhibition.
A Schematic drawing of the regulation of tonic inhibition with some implications for CNS disorders possibly associated with dysfunction of tonic inhibition (details will be shown below) is shown as Figure 1.
FIGURE 1
SENSORY FUNCTIONS
Tonic GABA conductances exist within ascending sensory pathways on each level, including spiny neurons of the dorsal horn in the spinal cord (), thalamic relay neurons (; Richardson et al., 2011), granule cells of the olfactory bulb (), the brain stem auditory pathway (), and the primary sensory cortex (Yamada et al., 2007; ; ). Tonic inhibition is thought to be important for sensory processing because it reduces the impact of low frequency excitation, thereby increasing its signal-to-noise ratio.
4,5,6,7-Tetrahydroisoxazolo(5,4-c)pyridin-3-ol (THIP) acts as an anti-nociceptive in rodent models of acute pain (; Munro et al., 2008; ). The anti-nociceptive effect is absent from δ- or α4-GABAA receptor null mutant mice (; ), indicating that tonic inhibition plays major roles in the regulation of acute nociception. The effects of THIP have been attributed to actions at supraspinal targets, such as thalamic relay neurons (Zorn and Enna, 1985; Rode et al., 2005; ). Tonic GABA currents mediated by the δ subunit also exist in the spinal cord dorsal horn (). Studies on δ subunit knock-out (KO) mice indicate that tonic inhibition likely regulates the late phase of nociceptor activity, thus corresponding to central sensitization (). This response may result from amplification of tonic inhibition caused by activity-dependent GABA spillover or induction of neurosteroids during early phase of nociception. Nociceptor activity in early phase was shown to be comparable between wild type (WT) and δ-GABAA receptor KO mice (). Therefore, a tonic inhibition in spinal cord neurons may also contribute to regulating central sensitization and acute nociception.
In the auditory thalamus, the medial geniculate body is essential for processing acoustic information. A recent study has demonstrated that age-related loss of inhibition in this area is more dominant in tonic rather than phasic inhibition (Richardson et al., 2013). Decreased expression of α4δ-GABAA receptors and down-regulation of glutamic acid decarboxylase (GAD) 67 have been found to be possible mechanisms underlying this difference (Richardson et al., 2013). Because the efficacy of auditory coding is directly correlated with the strength of GABAergic inhibition (; ), enhancement of tonic inhibition was proposed to be a potential strategy against age-related decline of auditory cognition. A reduction of tonic inhibition has been reported in the auditory cortex of hearing-lesioned rat (Yang et al., 2011). In this model, GAD67 was reduced in the affected region, resulting in down-regulation of both phasic and tonic inhibition. In addition, hearing-lesioned animals displayed tinnitus with a pitch in the hearing loss range, which was eliminated by the GABA transaminase inhibitor, vigabatrin, or by reducing the uptake of GABA by the GAT1 inhibitor, NO711.
COGNITIVE DYSFUNCTION AND FUNCTIONAL RECOVERY AFTER STROKE
Because cognition involves a group of mental processes such as memory, attention, understanding language, and learning, numerous brain regions are thus responsible for cognitive dysfunctions. The hippocampus plays a critical role in learning and memory, and recent evidence suggests that the α5-GABAA receptor is abundantly expressed in this brain region, and thus may be a therapeutic target for cognitive dysfunction (Sperk et al., 1997).
Down syndrome is caused by the trisomy for chromosome 21, and is the most frequent neurodevelopmental disorder of chromosomal origin. Almost all affected individuals exhibit cognitive impairment, with specific deficits in learning and memory mediated by hippocampal dysfunctions (). This phenotype is well replicated in the Ts65Dn mouse model of Down syndrome. The finding that low-dose picrotoxin restored hippocampal long-term potentiation in this model () subsequently led to the hypothesis of “excessive inhibition,” and was strongly recognized to play a pathological role in this syndrome. In support of this hypothesis, Ts65Dn mice were found to exhibit increased immunoreactivity of GAD65/67 and vesicular GABA transporter (vGAT; ; Perez-Cremades et al., 2010; Martinez-Cue et al., 2013). Numerous studies indicate that α5-GABAA receptor-mediated inhibition (mainly in the tonic form) reduces learning and memory. Mice deficient in the α5 subunit show better performance of cognitive functions compared with wild-type (; ; Yee et al., 2004). Similarly, rodents systemically administrated with various α5 subunit-selective negative allosteric modulators displayed a facilitation in learning and memory tasks, associated with increased long-term potentiation (Navarro et al., 2002; ,; ; ). Therefore, specific antagonism of the α5 subunit may be a potential therapeutic strategy against cognitive impairment in Down syndrome. Indeed, recent studies have revealed that cognitive function is ameliorated with the α5 subunit-selective negative allosteric modulators, α5IA, or RO4938581, in Ts65Dn mice without any side effects (; Martinez-Cue et al., 2013). RO4938581 is currently in clinical trials for adults with Down syndrome (the study is sponsored by Roche, and its outcomes have been made publicly available). The α5-selective negative allosteric modulators have also been shown as effective enhancers for learning and memory in other cognitive deficits induced by acute inflammation (Wang et al., 2012) or general anesthesia (Saab et al., 2010; Zurek et al., 2012) in mice, and by alcoholism in humans (Nutt et al., 2007; ).
In the aged brain, hippocampal tonic inhibition can regulate cognitive functions. Recent animal studies and human brain imaging of elderly individuals have indicated a strong positive correlation between hippocampal hyperactivity and cognitive impairment (Wilson et al., 2005; ). In support of the “excessive excitation” hypothesis, the positive (and not negative) allosteric modulator for the α5 subunit improves memory tasks in aged rats with cognitive deficits (Wilson et al., 2005; ). This hypothesis may be applied to autism spectrum disorders because antiepileptic drugs sometimes improve cognitive functions in these affected individuals (). α5 subunit selective allosteric modulators currently in clinical trials have shown promise as a potential therapeutic strategy for cognitive deficits in various CNS diseases.
Several reports have demonstrated that the inhibitory balance between phasic and tonic inhibition shifts to tonic after cortical lesion (; ). This shift may provide protection against cell death in the acute stage, and also prevent homeostatic plasticity during the recovery period. In a cortical stroke model, excessive tonic inhibition has been proposed as a novel pharmacological target for promoting recovery after stroke (). Therefore, negative allosteric modulators for the α5 subunit may be effective against learning and memory deficits as well as for dysfunctions after brain injury.
PSYCHIATRIC DISORDERS
Schizophrenia is generally recognized to develop from the disruption of various kinds of neurotransmission. Dysfunction in GABAergic transmission has drawn significant attention as a mechanism underlying cognitive deficits in schizophrenia (; ). Postmortem analyses and brain imaging of living schizophrenic subjects have revealed a deficiency in the synthesis of GABA resulting from reduced transcription of GAD67 (; Volk et al., 2000; ; Yoon et al., 2010). Results of studies investigating the expression of GABAA receptor subunits in postmortem tissue have been inconsistent. The expression of α1, α2, and α5 subunits have been reported to be increased (; ; ), decreased (), or unchanged (). Despite the limited number of reports investigating the expression of the δ subunit, several reports have shown decreased expression of this subunit in the prefrontal cortex (; Maldonado-Aviles et al., 2009). A considerable limitation of the postmortem tissue analyses in these studies is the chronic consumption of antipsychotics and/or benzodiazepines in the subjects. Furthermore, symptoms of schizophrenia dynamically change with the clinical stage. A recent study involving positron emission tomography (PET) using the highly selective α5 subunit ligand, [11C]Ro15-4513, revealed an inverse correlation between binding potential and severity of the negative symptoms in medication-free subjects (). Therefore, this result suggests that decreased expression of the α5 subunit may be involved in the pathophysiology of schizophrenia during the negative stage. Supporting this hypothesis, use of the positive allosteric modulator for the α5 subunit has been shown to improve the hyperactivity and cognitive dysfunctions in rat models of schizophrenia (; ). However, Redrobe et al. (2012) have shown that a negative allosteric modulator of the α5 subunit also attenuates cognitive deficits, using a different mouse model of schizophrenia. Interestingly, the authors also showed that hyperactivity was ameliorated by both positive and negative modulators for the α5 subunit in these mice. Excitatory and inhibitory biphasic changes induced by tonic conductance have been recently shown in single neurons with depolarizing reversal potential for GABA currents (Song et al., 2011). Therefore, an increase or decrease of tonic inhibition may result in net inhibitory effects in relevant neuronal circuits in this model. Further studies are required to validate the usefulness of α5 subunit selective allosteric modulators for the treatment of schizophrenia.
Neurosteroids, metabolites of progesterone, other sex hormones, and several stress-induced steroids are potent modulators of GABAA receptors (). In particular, the extrasynaptic δ-GABAA receptor shows higher sensitivity for neurosteroids compared with synaptic GABAA receptors (; Stell et al., 2003; see review ). Therefore, dysregulation of tonic inhibition may play a pivotal role in psychiatric disorders, such as anxiety and mood disorders, which are often associated with sex hormone alterations or stress. For example, expression of the δ subunit has been shown to decrease during pregnancy due to adaptive mechanisms against large elevation of progesterone metabolites (). The rapid decrease of neurosteroids after birth can thus induce the down-regulation of tonic inhibition, resulting in postpartum depression ().
In a rat model of premenstrual dystrophic disorders, withdrawal of progesterone leads to anxiety and increased seizure susceptibility, associated with up-regulation of the α4 subunit (Smith et al., 1998). In contrast, increased levels of neurosteroids during physiological ovarian cycles leads to reduction of anxiety and seizure susceptibility caused by up-regulation of the δ subunit (). This difference may thus suggest that neurosteroids can alter the effects of tonic GABA conductance by dose and/or exposure time-dependent mechanisms, thereby regulating the expression of receptor subunits. In accordance with this speculation, evaluating anxiety at puberty revealed that neurosteroids negatively modulated tonic inhibition by decreasing outward currents, via α4δ-GABAA receptors (Shen et al., 2007). This regulation was shown to contribute to psychiatric disorders during puberty, such as mood swings, anxiety, and anorexia ().
Excessive stress leads to physiological and behavioral responses resulting in numerous psychiatric disorders. The hypothalamic-pituitary-adrenal (HPA) axis plays an important role for mediating physiological responses by promoting stress-induced steroid synthesis (see review ). A recent study has demonstrated that stress-derived neurosteroid acts on δ-GABAA receptors of corticotrophin releasing hormone (CRH) neurons, biphasically modulating their excitability depending on the presence or absence of stress (). The study showed that stress decreased the activity of the outward-directed K+, Cl- co-transporter, potassium-chloride transporter 2 (KCC2), in CRH neurons, switching tonic GABA conductance from inhibitory to excitatory and resulting in increased activity of the HPA axis and elevated levels of corticosterone (). Because blockage of corticosterone synthesis prevents stress-induced anxiety, this positive feedback loop may be one of the mechanisms underlying stress-induced psychiatric disorders (Sarkar et al., 2011). Overall, emerging evidence has uncovered a bidirectional modification of tonic inhibition by neurosteroids, and thus may explain why increases in neurosteroids can lead to various types of psychiatric disorders, including depression and anxiety.
AUTISM SPECTRUM DISORDERS AND RELATED SYNDROMES
“Autism spectrum” encompasses a wide range of disorders, which can be divided into two groups with respect to their etiology: (1) recognizably distinct syndromes caused by mutations in specific genes or chromosomal loci, and (2) more common, genetically heterogeneous subjects, referred to as idiopathic autism (). The number of subjects in the first group is much lower than idiopathic autisms (), however their pathophysiology can be rigorously analyzed by using a genetic mouse model.
Fragile X syndrome (FXS) is a neurodevelopmental disorder caused by malfunction of the fragile X mental retardation 1 (FMR1) gene on the X chromosome, which encodes the FMR protein (FMRP; Verkerk et al., 1991). Common symptoms include intellectual disability, a distinctive physical phenotype, and autism-like behavior often associated with epilepsy. FMRP is known to regulate the mRNA transcription of various synaptic plasticity-associated proteins in concert with activation of metabotropic glutamate receptors (mGluR; ). mRNA of some GABAA receptor subunits, particularly the δ subunit, are targeted substrates of FMRP (Miyashiro et al., 2003; ). Dendritic localization of δ subunit mRNA has been shown to be regulated by mGluR activation under the presence of FMRP (), suggesting that tonic inhibition plays an important role for the homeostatic regulation of excitation-inhibition during development. Indeed, electrophysiological analysis in FMR1 KO mice revealed that tonic, but not phasic, inhibition in subicular pyramidal neurons is significantly decreased, with decreased expression of δ and α5 subunits in this region (). Decreased expression of the δ subunit protein has also been shown in the cortex and hippocampus of this mouse model (). Olmos-Serrano et al. (2010) demonstrated that FMR1 KO mice exhibit remarkably reduced tonic and phasic inhibitory currents in the amygdala principal neurons, with reduced GAD65 and GAD67 expression. This group also showed that THIP rescued neuronal hyperexcitability, in vitro, and ameliorated hyperexcitability, in vivo (Olmos-Serrano et al., 2010,2011; Figures 2A–C), indicating that tonic inhibition is a potent therapeutic target for FXS. In contrast, increased GAD65 and GAD67 expression was also observed in the cortex and hippocampus of FMR1 KO mice (; ), thus indicating regional differentiation of deregulation mechanisms of inhibition.
FIGURE 2
Similar presynaptic dysfunction in GABAergic neurotransmission has been proposed as a mechanism underlying the autism spectrum-related disorder, Rett syndrome. Mice lacking the causal gene, methyl CpG binding protein 2, from GABAergic neurons recapitulate phenotypes as those seen in Rett syndrome, with decreased GABA levels, reduced expression of GAD65/67, and miniature inhibitory postsynaptic current amplitudes in cortical pyramidal neurons (
Findings from our recent study have shown decreased tonic inhibition as a mechanism underlying cerebellar ataxia in the autism spectrum-related disorder, Angelman syndrome (
Accumulating evidence has indicated that the chromosome 15q11-13 abnormalities are highly correlated with the prevalence of idiopathic autisms. Genetic multi-linkage analysis has identified GABAA receptor α5 and β3 subunit genes on 15q11-13 that contribute to autism susceptibility (McCauley et al., 2004). Furthermore, this region is one of the most common loci where copy number variants have been observed in idiopathic autisms. The prevalence of 15q11–13 duplications in idiopathic autisms has been estimated to be at 3% (
NON-SYNAPTICALLY RELEASED GABA INDUCES TONIC DEPOLARIZATION DURING CORTICOGENESIS
Gamma-aminobutyric acid induces depolarization and hyperpolarization in the immature and adult brain, respectively. The GABAA receptor is a Cl- channel (also permeable for HCO3-), and thus the developmental switch of GABA-mediated depolarization to hyperpolarization is induced by changes in the transmembranous Cl- gradient, from its efflux to influx, respectively. This change is regulated by cation-Cl- cotransporters [Na–K–Cl cotransporter 1 (NKCC1), Cl- uptake; and KCC2, Cl- extrusion]. Furthermore, in immature neurons the release mechanism of GABA is non-vesicular and non-synaptic, and therefore GABA-mediated activity is generally tonic. These tonic depolarizing (and excitatory on occasion) GABA actions are necessary for neurogenesis, differentiation, migration, and synaptogenesis (Figure 3).
FIGURE 3

Multi-modal actions of tonic modulation of the GABAA receptor during corticogenesis. In the ventricular zone (VZ) and subventricular zone (SVZ), ambient GABA affects neurogenesis. Post-mitotic neurons migrating to the cortical plate are tonically depolarized by non-synaptic and non-vesicular ambient GABA, released from tangentially migrating GABA neurons prior to forming synapses, and changing migratory pace. GABA also acts in an autocrine manner to accelerate tangential migration. Vesicular release of GABA, which remains depolarizing, may contribute to synapse formation. Following the establishment of GABAergic synapses (and prior to hyperpolarization), GABA acts as an excitatory neurotransmitter due to high intracellular Cl- concentration levels, predominantly resulting from Na–K–Cl cotransporter 1 (NCC1) followed by K–Cl cotransporter 2 (KCC2). Green circle: ambient GABA. Adapted from
During development, GABAA receptor subunits exhibit a completely different expression pattern (
GABAA receptor-mediated signaling affects neurogenesis during development. A pioneering study by
In the neocortex, different classes of neurons, pyramidal cortical neurons, and GABAergic interneurons, originate from different sources and have distinct migration routes. Glutamatergic pyramidal neurons radially migrate from the dorsal telencephalic VZ where they are generated via radial glial scaffolding toward the cortical plate. In contrast, GABAergic interneurons arising from the medial ganglionic eminence (MGE) tangentially migrate into the cerebral wall (for review, see Marïn and Rubenstein, 2001). GABAA receptor signaling is well known to have distinct effects on radially or tangentially migrating neurons.
Tonic activation of GABAA receptors precedes phasic activation in early development (for review, see Owens and Kriegstein, 2002), hence its possible requirement for synaptogenesis during this period (
PERTURBATION OF TONIC DEPOLARIZATION MAY CAUSE BRAIN MAL-DEVELOPMENT
As mentioned previously in this review, tonic depolarizing responses to ambient GABA is locally controlled by uptake and/or release mechanisms allowing GABAA receptor-mediated actions to control a variety of developmental events in a time- and region-specific fashion. Thus, a defect in GABAA receptor-mediated multimodal functions during development can cause neuronal circuit dysfunctions hence neurological disorders. Therefore, use of GABAA receptor activating drugs to enhance inhibition in the immature brain may result in unexpected deleterious effects. A growing number of studies in immature animal models have demonstrated degenerative effects of several anesthetics on neuronal structure and brain functions, such as social behaviors, fear conditioning, and spatial reference memory tasks (
Neocortical malformations, such as polymicrogyria show the presence of cortical cells in heterotopic positions; often caused by a disruption in neuronal migration (Walsh, 1999;
CONCLUSION
This review has focused on the recent progress in understanding the impact of dysregulated tonic inhibition in CNS diseases. Accumulating evidence highlights the pathophysiological significance of dysregulated tonic inhibition in a number of neurodevelopmental disorders, psychiatric disorders, and cognitive dysfunctions (see Figure 1). In addition to pharmacological progress, animal model studies are presently opening the door for practical medicine. However, an overview of these studies also presents problems for clinical application. For example, the same phenotype may result from a decrease or increase of tonic inhibition. Therefore, the net shift from excitation to inhibition may not always occur with a modulation of tonic inhibition. This paradox is possibly due to the complexity of network regulation by tonic conductance. For example, simultaneous receptor activation in either inhibitory or excitatory neurons, or multiple mechanisms can be responsible for changing membrane properties, such as shunting inhibition and a shift in intracellular Cl- concentration. Although temporal characteristics of tonic inhibition are weak, maintaining network functions can possibly regulate its strength, thus suggesting a narrow therapeutic range for such modulators. A detailed assessment of these mechanisms would therefore be needed to develop a therapeutic strategy.
This review also discussed tonic depolarization induced by ambient GABA during early development, where the release of GABA is possibly non-vesicular and occurring before synaptic organization (see Figure 3). Thus far, very few studies have addressed this series of events as a potential risk factor for CNS diseases. Therefore, research focused on the pathological effects of multimodal functions of GABA during neurodevelopment may shed light on understanding the pathology of neurodevelopmental disorders in which GABA is known to play a role, for example in schizophrenia and autism spectrum disorders.
Statements
Acknowledgments
We would like to thank Dr. S. Saito for comments on the manuscript.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
REFERENCES
1
AdeK. K.JanssenM. J.OrtinskiP. I.ViciniS. (2008). Differential tonic GABA conductances in striatal medium spiny neurons.J. Neurosci.281185–1197. 10.1523/JNEUROSCI.3908-07.2008
2
AduseiD. C.PaceyL. K.ChenD.HampsonD. R. (2010). Early developmental alterations in GABAergic protein expression in fragile X knockout mice.Neuropharmacology59167–171. 10.1016/j.neuropharm.2010.05.002
3
AkbarianS.HuntsmanM. M.KimJ. J.TafazzoliA.PotkinS. G.BunneyW. E.et al (1995a). GABAA receptor subunit gene expression in human prefrontal cortex: comparison of schizophrenics and controls.Cereb. Cortex5550–560. 10.1093/cercor/5.6.550
4
AkbarianS.KimJ. J.PotkinS. G.HagmanJ. O.TafazzoliA.BunneyW. E.et al (1995b). Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics.Arch. Gen. Psychiatry52258–266. 10.1001/archpsyc.1995.03950160008002
5
AndängM.Hjerling-LefflerJ.MolinerA.LundgrenT. K.Castelo-BrancoG.NanouE.et al (2008). Histone H2AX-dependent GABAA receptor regulation of stem cell proliferation.Nature451460–464. 10.1038/nature06488
6
AokiC.SabaliauskasN.ChowdhuryT.MinJ. Y.ColacinoA. R.LaurinoK.et al (2012). Adolescent female rats exhibiting activity-based anorexia express elevated levels of GABAA receptor α4 and δ subunits at the plasma membrane of hippocampal CA1 spines.Synapse66391–407. 10.1002/syn.21528
7
AsaiY.TakanoA.ItoH.OkuboY.MatsuuraM.OtsukaA.et al (2008). GABAA/Benzodiazepine receptor binding in patients with schizophrenia using [11C]Ro15-4513, a radioligand with relatively high affinity for α5 subunit.Schizophr. Res.99333–340. 10.1016/j.schres.2007.10.014
8
AtackJ. R. (2010). Preclinical and clinical pharmacology of the GABAA receptor α5 subtype-selective inverse agonist α5IA.Pharmacol. Ther.12511–26. 10.1016/j.pharmthera.2009.09.001
9
AtackJ. R.BayleyP. J.SeabrookG. R.WaffordK. A.MckernanR. M.DawsonG. R. (2006). L-655,708 enhances cognition in rats but is not proconvulsant at a dose selective for α5-containing GABAA receptors.Neuropharmacology511023–1029. 10.1016/j.neuropharm.2006.04.018
10
AtackJ. R.MaubachK. A.WaffordK. A.O’ConnorD.RodriguesA. D.EvansD. C.et al (2009). In vitro and in vivo properties of 3-tert-butyl-7-(5-methylisoxazol-3-yl)-2-(1-methyl-1H-1,2,4-triazol-5- ylmethoxy)-pyrazolo[1,5-d]-[1,2,4] triazine (MRK-016), a GABAA receptor α5 subtype-selective inverse agonist.J. Pharmacol. Exp. Ther.331470–484. 10.1124/jpet.109.157636
11
BallardT. M.KnoflachF.PrinssenE.BorroniE.VivianJ. A.BasileJ.et al (2009). RO4938581, a novel cognitive enhancer acting at GABAA α5 subunit-containing receptors.Psychopharmacology (Berl.)202207–223. 10.1007/s00213-008-1357-7
12
BassellG. J.WarrenS. T. (2008). Fragile X syndrome: loss of local mRNA regulation alters synaptic development and function.Neuron60201–214. 10.1016/j.neuron.2008.10.004
13
BeharT. N.LiY. X.TranH. T.MaW.DunlapV.ScottC.et al (1996). GABA stimulates chemotaxis, and chemokinesis of embryonic cortical neurons via calcium-dependent mechanisms.J. Neurosci.161808–1818.
14
BeharT. N.SchaffnerA. E.ScottC. A.GreeneC. L.BarkerJ. L. (2000). GABA receptor antagonists modulate postmitotic cell migration in slice cultures of embryonic rat cortex.Cereb. Cortex10899–909. 10.1093/cercor/10.9.899
15
BeharT. N.SchaffnerA. E.ScottC. A.O’ConnellC.BarkerJ. L. (1998). Differential response of cortical plate and ventricular zone cells to GABA as a migration stimulus.J. Neurosci.186378–6387.
16
BeharT. N.SmithS. V.KennedyR. T.McKenzieJ. M.MaricI.BarkerJ. L. (2001). GABAB receptors mediate motility signals for migrating embryonic cortical cells.Cereb. Cortex11744–753. 10.1093/cercor/11.8.744
17
BelichenkoP. V.KleschevnikovA. M.MasliahE.WuC.Takimoto-KimuraR.SalehiA.et al (2009). Excitatory-inhibitory relationship in the fascia dentata in the Ts65Dn mouse model of Down syndrome.J. Comp. Neurol.512453–466. 10.1002/cne.21895
18
Ben-AriY. (2002). Excitatory actions of GABA during development: the nature of the nurture.Nat. Rev. Neurosci.3728–739. 10.1038/nrn920
19
Ben-AriY.GaiarsaJ. L.TyzioR.KhazipovR. (2007). GABA: a pioneer transmitter that excites immature neurons and generates primitive oscillations.Physiol. Rev.871215–1284. 10.1152/physrev.00017.2006
20
BianchiM. T.MacDonaldR. L. (2003). Neurosteroids shift partial agonist activation of GABAA receptor channels from low- to high-efficacy gating patterns.J. Neurosci.2310934–10943.
21
BoninR. P.LabrakakisC.EngD. G.WhissellP. D.De KoninckY.OrserB. A. (2011). Pharmacological enhancement of δ-subunit-containing GABAA receptors that generate a tonic inhibitory conductance in spinal neurons attenuates acute nociception in mice.Pain1521317–1326. 10.1016/j.pain.2011.02.011
22
BortoneD.PolleuxF. (2009). KCC2 expression promotes the termination of cortical interneuron migration in a voltage-sensitive calcium-dependent manner.Neuron6253–71. 10.1016/j.neuron.2009.01.034
23
BraudeauJ.DelatourB.DuchonA.PereiraP. L.DauphinotL.De ChaumontF.et al (2011). Specific targeting of the GABA-A receptor α5 subtype by a selective inverse agonist restores cognitive deficits in Down syndrome mice.J. Psychopharmacol.251030–1042. 10.1177/0269881111405366
24
BrickleyS. G.Cull-CandyS. G.FarrantM. (1996). Development of a tonic form of synaptic inhibition in rat cerebellar granule cells resulting from persistent activation of GABAA receptors.J. Physiol.497753–759.
25
BrickleyS. G.ModyI. (2012). Extrasynaptic GABAA receptors: their function in the CNS and implications for disease.Neuron7323–34. 10.1016/j.neuron.2011.12.012
26
BrickleyS. G.RevillaV.Cull-CandyS. G.WisdenW.FarrantM. (2001). Adaptive regulation of neuronal excitability by a voltage-independent potassium conductance.Nature40988–92. 10.1038/35051086
27
BrightD. P.RenziM.BartramJ.McGeeT. P.MacKenzieG.HosieA. M.et al (2011). Profound desensitization by ambient GABA limits activation of δ-containing GABAA receptors during spillover.J. Neurosci.31753–763. 10.1523/JNEUROSCI.2996-10.2011
28
BrunigI.ScottiE.SidlerC.FritschyJ. M. (2002). Intact sorting, targeting, and clustering of γ-aminobutyric acid A receptor subtypes in hippocampal neurons in vitro.J. Comp. Neurol.44343–55. 10.1002/cne.10102
29
CamposM. L.De CaboC.WisdenW.JuizJ. M.MerloD. (2001). Expression of GABAA receptor subunits in rat brainstem auditory pathways: cochlear nuclei, superior olivary complex and nucleus of the lateral lemniscus.Neuroscience102625–638. 10.1016/S0306-4522(00)00525-X
30
CaraiscosV. B.ElliottE. M.You-TenK. E.ChengV. Y.BelelliD.NewellJ. G.et al (2004). Tonic inhibition in mouse hippocampal CA1 pyramidal neurons is mediated by α5 subunit-containing γ-aminobutyric acid type A receptors.Proc. Natl. Acad. Sci. U.S.A.1013662–3667. 10.1073/pnas.0307231101
31
CarlesimoG. A.MarottaL.VicariS. (1997). Long-term memory in mental retardation: evidence for a specific impairment in subjects with Down’s syndrome.Neuropsychologia3571–79. 10.1016/S0028-3932(96)00055-3
32
ChandraD.JiaF.LiangJ.PengZ.SuryanarayananA.WernerD. F.et al (2006). GABAA receptor α 4 subunits mediate extrasynaptic inhibition in thalamus and dentate gyrus and the action of gaboxadol.Proc. Natl. Acad. Sci. U.S.A.10315230–15235. 10.1073/pnas.0604304103
33
ChaoH. T.ChenH.SamacoR. C.XueM.ChahrourM.YooJ.et al (2010). Dysfunction in GABA signalling mediates autism-like stereotypies and Rett syndrome phenotypes.Nature468263–269. 10.1038/nature09582
34
ChiuC. S.BrickleyS.JensenK.SouthwellA.McKinneyS.Cull-CandyS.et al (2005). GABA transporter deficiency causes tremor, ataxia, nervousness, and increased GABA-induced tonic conductance in cerebellum.J. Neurosci.253234–3245. 10.1523/JNEUROSCI.3364-04.2005
35
ClarksonA. N.HuangB. S.MacIsaacS. E.ModyI.CarmichaelS. T. (2010). Reducing excessive GABA-mediated tonic inhibition promotes functional recovery after stroke.Nature468305–309. 10.1038/nature09511
36
CoghlanS.HorderJ.InksterB.MendezM. A.MurphyD. G.NuttD. J. (2012). GABA system dysfunction in autism and related disorders: from synapse to symptoms.Neurosci. Biobehav. Rev.362044–2055. 10.1016/j.neubiorev.2012.07.005
37
CollinsonN.KuenziF. M.JarolimekW.MaubachK. A.CothliffR.SurC.et al (2002). Enhanced learning and memory and altered GABAergic synaptic transmission in mice lacking the α 5 subunit of the GABAA receptor.J. Neurosci.225572–5580.
38
CopeD. W.Di GiovanniG.FysonS. J.OrbanG.ErringtonA. C.LorinczM. L.et al (2009). Enhanced tonic GABAA inhibition in typical absence epilepsy.Nat. Med.151392–1398. 10.1038/nm.2058
39
CopeD. W.HughesS. W.CrunelliV. (2005). GABAA receptor-mediated tonic inhibition in thalamic neurons.J. Neurosci.2511553–11563. 10.1523/JNEUROSCI.3362-05.2005
40
CrestaniF.KeistR.FritschyJ. M.BenkeD.VogtK.PrutL.et al (2002). Trace fear conditioning involves hippocampal α5 GABAA receptors.Proc. Natl. Acad. Sci. U.S.A.998980–8985. 10.1073/pnas.142288699
41
CuriaG.PapouinT.SeguelaP.AvoliM. (2009). Downregulation of tonic GABAergic inhibition in a mouse model of fragile X syndrome.Cereb. Cortex191515–1520. 10.1093/cercor/bhn159
42
CuzonV. C.YehH. H. (2011). GABAA receptor subunit profiles of tangentially migrating neurons derived from the medial ganglionic eminence.Cereb. Cortex211792–1802. 10.1093/cercor/bhq247
43
CuzonV. C.YehP. W.ChengQ.YehH. H. (2006). Ambient GABA promotes cortical entry of tangentially migrating cells derived from the medial ganglionic eminence.Cereb. Cortex161377–1388. 10.1093/cercor/bhj084
44
DamgaardT.PlathN.NeillJ. C.HansenS. L. (2011). Extrasynaptic GABAA receptor activation reverses recognition memory deficits in an animal model of schizophrenia.Psychopharmacology214403–413. 10.1007/s00213-010-2039-9
45
DaviesP. A.HannaM. C.HalesT. G.KirknessE. F. (1997). Insensitivity to anaesthetic agents conferred by a class of GABAA receptor subunit.Nature385820–823. 10.1038/385820a0
46
DawsonG. R.MaubachK. A.CollinsonN.CobainM.EverittB. J.MacLeodA. M.et al (2006). An inverse agonist selective for α5 subunit-containing GABAA receptors enhances cognition.J. Pharmacol. Exp. Ther.3161335–1345. 10.1124/jpet.105.092320
47
De BiasiS.Vitellaro-ZuccarelloL.BrechaN. C. (1998). Immunoreactivity for the GABA transporter-1 and GABA transporter-3 is restricted to astrocytes in the rat thalamus.A light and electron-microscopic immunolocalization. Neuroscience83815–828. 10.1016/S0306-4522(97)00414-4
48
DemarqueM.RepresaA.BecqH.KhalilovI.Ben-AriY.AniksztejnL. (2002). Paracrine intercellular communication by a Ca2+ and SNARE-independent release of GABA and glutamate prior to synapse formation.Neuron361051–1061. 10.1016/S0896-6273(02)01053-X
49
DenterD. G.HeckN.RiedemannT.WhiteR.KilbW.LuhmannH. J. (2010). GABAC receptors are functionally expressed in the intermediate zone and regulate radial migration in the embryonic mouse neocortex.Neuroscience167124–134. 10.1016/j.neuroscience.2010.01.049
50
de Villers-SidaniE.AlzghoulL.ZhouX.SimpsonK. L.LinR. C.MerzenichM. M. (2010). Recovery of functional and structural age-related changes in the rat primary auditory cortex with operant training.Proc. Natl. Acad. Sci. U.S.A.10713900–13905. 10.1073/pnas.1007885107
51
DiazM. R.WadleighA.HughesB. A.WoodwardJ. J.ValenzuelaC. F. (2011). Bestrophin1 channels are insensitive to ethanol and do not mediate tonic GABAergic currents in cerebellar granule cells.Front. Neurosci. 5:148. 10.3389/fnins.2011.00148
52
DictenbergJ. B.SwangerS. A.AntarL. N.SingerR. H.BassellG. J. (2008). A direct role for FMRP in activity-dependent dendritic mRNA transport links filopodial-spine morphogenesis to fragile X syndrome.Dev. Cell14926–939. 10.1016/j.devcel.2008.04.003
53
Di MartinoA.TuchmanR. F. (2001). Antiepileptic drugs: affective use in autism spectrum disorders.Pediatr. Neurol.25199–207. 10.1016/S0887-8994(01)00276-4
54
Dvorák,K.FeitJ. (1977). Migration of neuroblasts through partial necrosis of the cerebral cortex in newborn rats-contribution to the problems of morphological development and developmental period of cerebral microgyria.Histological and autoradiographical study. Acta Neuropathol.38203–212. 10.1007/BF00688066
55
EgawaK.AsahinaN.ShiraishiH.KamadaK.TakeuchiF.NakaneS.et al (2008). Aberrant somatosensory-evoked responses imply GABAergic dysfunction in Angelman syndrome.Neuroimage39593–599. 10.1016/j.neuroimage.2007.09.006
56
EgawaK.KitagawaK.InoueK.TakayamaM.TakayamaC.SaitohS.et al (2012). Decreased tonic inhibition in cerebellar granule cells causes motor dysfunction in a mouse model of Angelman syndrome.Sci. Transl. Med.4163–157.
57
EgawaK.YamadaJ.FurukawaT.YanagawaY.FukudaA. (2013). Cl- homeodynamics in gap-junction-coupled astrocytic networks on activation of GABAergic synapses.J. Physiol. 591(Pt.16)3901–3917. 10.1113/jphysiol.2013.257162
58
El IdrissiA.DingX. H.ScaliaJ.TrenknerE.BrownW. T.DobkinC. (2005). Decreased GABAA receptor expression in the seizure-prone fragile X mouse.Neurosci. Lett.377141–146. 10.1016/j.neulet.2004.11.087
59
EnnaS. J.McCarsonK. E. (2006). The role of GABA in the mediation and perception of pain.Adv. Pharmacol.541–27. 10.1016/S1054-3589(06)54001-3
60
EwersM.SperlingR. A.KlunkW. E.WeinerM. W.HampelH. (2011). Neuroimaging markers for the prediction and early diagnosis of Alzheimer’s disease dementia.Trends Neurosci.34430–442. 10.1016/j.tins.2011.05.005
61
FarrantM.NusserZ. (2005). Variations on an inhibitory theme: phasic and tonic activation of GABAA receptors.Nat. Rev. Neurosci.6215–229. 10.1038/nrn1625
62
FrancisF.MeyerG.Fallet-BiancoC.MorenoS.KappelerC.SocorroA. C.et al (2006). Human disorders of cortical development: from past to present.Eur. J. Neurosci.23877–893. 10.1111/j.1460-9568.2006.04649.x
63
FritschyJ. M.PaysanJ.EnnaA.MohlerH. (1994). Switch in the expression of rat GABAA-receptor subtypes during postnatal development: an immunohistochemical study.J. Neurosci.145302–5324.
64
FukudaA.WangT. (2013). A perturbation of multimodal GABA functions underlying the formation of focal cortical malformations: assessments by using animal models.Neuropathology33480–486. 10.1111/neup.12021
65
GillK. M.LodgeD. J.CookJ. M.ArasS.GraceA. A. (2011). A novel α5 GABAAR-positive allosteric modulator reverses hyperactivation of the dopamine system in the MAM model of schizophrenia.Neuropsychopharmacology361903–1911. 10.1038/npp.2011.76
66
GleichO.HamannI.KlumpG. M.KittelM.StrutzJ. (2003). Boosting GABA improves impaired auditory temporal resolution in the gerbil.Neuroreport141877–1880. 10.1097/01.wnr.0000089569.45990.74
67
GlykysJ.ModyI. (2006). Hippocampal network hyperactivity after selective reduction of tonic inhibition in GABAA receptor α5 subunit-deficient mice.J. Neurophysiol.952796–2807. 10.1152/jn.01122.2005
68
GlykysJ.ModyI. (2007). The main source of ambient GABA responsible for tonic inhibition in the mouse hippocampus.J. Physiol.5821163–1178. 10.1113/jphysiol.2007.134460
69
GuidottiA.AutaJ.DavisJ. M.DongE.GraysonD. R.VeldicM.et al (2005). GABAergic dysfunction in schizophrenia: new treatment strategies on the horizon.Psychopharmacology180191–205. 10.1007/s00213-005-2212-8
70
HamannM.RossiD. J.AttwellD. (2002). Tonic and spillover inhibition of granule cells control information flow through cerebellar cortex.Neuron33625–633. 10.1016/S0896-6273(02)00593-7
71
HashimotoT.VolkD. W.EgganS. M.MirnicsK.PierriJ. N.SunZ.et al (2003). Gene expression deficits in a subclass of GABA neurons in the prefrontal cortex of subjects with schizophrenia.J. Neurosci.236315–6326.
72
HaydarT. F.WangF.SchwartzM. L.RakicP. (2000). Differential modulation of proliferation in the neocortical ventricular and subventricular zones.J. Neurosci.205764–5774.
73
HeckN.KilbW.ReiprichP.KubotaH.FurukawaT.FukudaA.et al (2007). GABA-A receptors regulate neocortical neuronal migration in vitro and in vivo.Cereb. Cortex17138–148. 10.1093/cercor/bhj135
74
HejaL.NyitraiG.KekesiO.DobolyiA.SzaboP.FiathR.et al (2012). Astrocytes convert network excitation to tonic inhibition of neurons.BMC Biol. 10:26. 10.1186/1741-7007-10-26
75
HewittS. A.WamsteekerJ. I.KurzE. U.BainsJ. S. (2009). Altered chloride homeostasis removes synaptic inhibitory constraint of the stress axis.Nat. Neurosci.12438–443. 10.1038/nn.2274
76
HinesR. M.DaviesP. A.MossS. J.MaguireJ. (2012). Functional regulation of GABAA receptors in nervous system pathologies.Curr. Opin. Neurobiol.22552–558. 10.1016/j.conb.2011.10.007
77
Hoestgaard-JensenK.DalbyN. O.WolinskyT. D.MurpheyC.JonesK. A.RottlanderM.et al (2010). Pharmacological characterization of a novel positive modulator at α4β3δ-containing extrasynaptic GABAA receptors.Neuropharmacology58702–711. 10.1016/j.neuropharm.2009.12.023
78
HogartA.NagarajanR. P.PatzelK. A.YasuiD. H.LasalleJ. M. (2007). 15q11-13 GABAA receptor genes are normally biallelically expressed in brain yet are subject to epigenetic dysregulation in autism-spectrum disorders.Hum. Mol. Genet.16691–703. 10.1093/hmg/ddm014
79
ImbrosciB.NeubacherU.WhiteR.EyselU. T.MittmannT. (2012). Shift from phasic to tonic GABAergic transmission following laser-lesions in the rat visual cortex.Pflugers Arch.465879–893. 10.1007/s00424-012-1191-y
80
ImpagnatielloF.GuidottiA. R.PesoldC.DwivediY.CarunchoH.PisuM. G.et al (1998). A decrease of reelin expression as a putative vulnerability factor in schizophrenia.Proc. Natl. Acad. Sci. U.S.A.9515718–15723. 10.1073/pnas.95.26.15718
81
InadaH.WatanabeM.UchidaT.IshibashiH.WakeH.NemotoT.et al (2011). GABA regulates the multidirectional tangential migration of GABAergic interneurons in living neonatal mice.PLoS ONE 6:e27048. 10.1371/journal.pone.0027048
82
InoueK.FurukawaT.KumadaT.YamadaJ.WangT.InoueR.et al (2012). Taurine inhibits the K+–Cl--cotransporter KCC2 to regulate embryonic Cl- homeostasis via the with-no-lysine (WNK) protein kinase signaling pathway.J. Biol. Chem.28720839–20850. 10.1074/jbc.M111.319418
83
IshikawaM.MizukamiK.IwakiriM.HidakaS.AsadaT. (2004). Immunohistochemical and immunoblot study of GABAA α1 and β2/3 subunits in the prefrontal cortex of subjects with schizophrenia and bipolar disorder.Neurosci. Res.5077–84. 10.1016/j.neures.2004.06.006
84
JensenM. L.WaffordK. A.BrownA. R.BelelliD.LambertJ. J.MirzaN. R. (2013). A study of subunit selectivity, mechanism and site of action of the δ selective compound 2 (DS2) at human recombinant and rodent native GABAA receptors.Br. J. Pharmacol.1681118–1132. 10.1111/bph.12001
85
Jevtovic-TodorovicV.HartmanR. E.IzumiY.BenshoffN. D.DikranianK.ZorumskiC. F.et al (2003). Early exposure to common anesthetic agents causes widespread neurodegeneration in the developing rat brain and persistent learning deficits.J. Neurosci.23876–882.
86
JiangY. H.ArmstrongD.AlbrechtU.AtkinsC. M.NoebelsJ. L.EicheleG.et al (1998). Mutation of the Angelman ubiquitin ligase in mice causes increased cytoplasmic p53 and deficits of contextual learning and long-term potentiation.Neuron21799–811. 10.1016/S0896-6273(00)80596-6
87
KanedaM.FarrantM.Cull-CandyS. G. (1995). Whole-cell and single-channel currents activated by GABA and glycine in granule cells of the rat cerebellum.J. Physiol. 485(Pt2)419–435.
88
KasugaiY.SwinnyJ. D.RobertsJ. D.DaleziosY.FukazawaY.SieghartW.et al (2010). Quantitative localisation of synaptic and extrasynaptic GABAA receptor subunits on hippocampal pyramidal cells by freeze-fracture replica immunolabelling.Eur. J. Neurosci.321868–1888. 10.1111/j.1460-9568.2010.07473.x
89
KennedyR. T.ThompsonJ. E.VickroyT. W. (2002). In vivo monitoring of amino acids by direct sampling of brain extracellular fluid at ultralow flow rates and capillary electrophoresis.J. Neurosci. Methods11439–49. 10.1016/S0165-0270(01)00506-4
90
KersanteF.RowleyS. C.PavlovI.Gutierrez-MecinasM.SemyanovA.ReulJ. M.et al (2013). A functional role for both γ-aminobutyric acid (GABA) transporter-1 and GABA transporter-3 in the modulation of extracellular GABA and GABAergic tonic conductances in the rat hippocampus.J. Physiol.5912429–2441. 10.1113/jphysiol.2012.246298
91
KishinoT.LalandeM.WagstaffJ. (1997). UBE3A/E6-AP mutations cause Angelman syndrome.Nat. Genet.1570–73. 10.1038/ng0197-70
92
KleschevnikovA. M.BelichenkoP. V.VillarA. J.EpsteinC. J.MalenkaR. C.MobleyW. C. (2004). Hippocampal long-term potentiation suppressed by increased inhibition in the Ts65Dn mouse, a genetic model of Down syndrome.J. Neurosci.248153–8160. 10.1523/JNEUROSCI.1766-04.2004
93
KohM. T.Rosenzweig-LipsonS.GallagherM. (2013). Selective GABAA α5 positive allosteric modulators improve cognitive function in aged rats with memory impairment.Neuropharmacology64145–152. 10.1016/j.neuropharm.2012.06.023
94
Krogsgaard-LarsenP.FrolundB.LiljeforsT.EbertB. (2004). GABAA agonists and partial agonists: THIP (gaboxadol) as a non-opioid analgesic and a novel type of hypnotic.Biochem. Pharmacol.681573–1580. 10.1016/j.bcp.2004.06.040
95
Krook-MagnusonE. I.LiP.PaluszkiewiczS. M.HuntsmanM. M. (2008). Tonically active inhibition selectively controls feedforward circuits in mouse barrel cortex.J. Neurophysiol.100932–944. 10.1152/jn.01360.2007
96
KudielkaB. M.KirschbaumC. (2005). Sex differences in HPA axis responses to stress: a review.Biol. Psychol.69113–132. 10.1016/j.biopsycho.2004.11.009
97
LabarreraC.LondonM.AngeloK. (2013). Tonic inhibition sets the state of excitability in olfactory bulb granule cells.J. Physiol.5911841–1850. 10.1113/jphysiol.2012.241851
98
LambertJ. J.BelelliD.PedenD. R.VardyA. W.PetersJ. A. (2003). Neurosteroid modulation of GABAA receptors.Prog. Neurobiol.7167–80. 10.1016/j.pneurobio.2003.09.001
99
LaurieD. J.WisdenW.SeeburgP. H. (1992). The distribution of thirteen GABAA receptor subunit mRNAs in the rat brain.III. Embryonic and postnatal development. J. Neurosci.124151–4172.
100
LeeS.YoonB. E.BerglundK.OhS. J.ParkH.ShinH. S.et al (2010). Channel-mediated tonic GABA release from glia.Science330790–796. 10.1126/science.1184334
101
LewisD. A.HashimotoT.VolkD. W. (2005). Cortical inhibitory neurons and schizophrenia.Nat. Rev. Neurosci.6312–324. 10.1038/nrn1648
102
LewisD. A.VolkD. W.HashimotoT. (2004). Selective alterations in prefrontal cortical GABA neurotransmission in schizophrenia: a novel target for the treatment of working memory dysfunction.Psychopharmacology174143–150. 10.1007/s00213-003-1673-x
103
LiuZ.NeffR. A.BergD. K. (2006). Sequential interplay of nicotinic and GABAergic signaling guides neuronal development.Science3141610–1613. 10.1126/science.1134246
104
LoepkeA. W.IstaphanousG. K.McAuliffeJ. J.IIIMilesL.HughesE. A.McCannJ. C.et al (2009). The effects of neonatal isoflurane exposure in mice on brain cell viability, adult behavior, learning, and memory.Anesth. Analg.10890–104. 10.1213/ane.0b013e31818cdb29
105
López-BenditoG.Luján,R.ShigemotoR.GanterP.PaulsenOMolnár,Z. (2003). Blockade of GABAB receptors alters the tangential migration of cortical neurons.Cereb. Cortex13932–942. 10.1093/cercor/13.9.932
106
LossieA. C.WhitneyM. M.AmidonD.DongH. J.ChenP.TheriaqueD.et al (2001). Distinct phenotypes distinguish the molecular classes of Angelman syndrome.J. Med. Genet.38834–845. 10.1136/jmg.38.12.834
107
LoTurcoJ. J.OwensD. F.HeathM. J.DavisM. B.KriegsteinA. R. (1995). GABA and glutamate depolarize cortical progenitor cells and inhibit DNA synthesis.Neuron151287–1298. 10.1016/0896-6273(95)90008-X
108
MaW.BarkerJ. L. (1995). Complementary expressions of transcripts encoding GAD67 and GABAA receptor α4, β1, and γ1 subunits in the proliferative zone of the embryonic rat central nervous system.J. Neurosci.152547–2560.
109
MaguireJ.ModyI. (2008). GABAAR plasticity during pregnancy: relevance to postpartum depression.Neuron59207–213. 10.1016/j.neuron.2008.06.019
110
MaguireJ. L.StellB. M.RafizadehM.ModyI. (2005). Ovarian cycle-linked changes in GABAA receptors mediating tonic inhibition alter seizure susceptibility and anxiety.Nat. Neurosci.8797–804. 10.1038/nn1469
111
Maldonado-AvilesJ. G.CurleyA. A.HashimotoT.MorrowA. L.RamseyA. J.O’DonnellP.et al (2009). Altered markers of tonic inhibition in the dorsolateral prefrontal cortex of subjects with schizophrenia.Am. J. Psychiatry166450–459. 10.1176/appi.ajp.2008.08101484
112
ManentJ. B.DemarqueM.JorqueraI.PellegrinoC.Ben-AriY.AniksztejnL.et al (2005). A noncanonical release of GABA and glutamate modulates neuronal migration.J. Neurosci.254755–4765. 10.1523/JNEUROSCI.0553-05.2005
113
MarïnORubensteinJ. L. R. (2001). A long, remarkable journey: tangential migration in the telencephalon.Nat. Rev. Neurosci.2780–790. 10.1038/35097509
114
Martinez-CueC.MartinezP.RuedaN.VidalR.GarciaS.VidalV.et al (2013). Reducing GABAA α5 receptor-mediated inhibition rescues functional and neuromorphological deficits in a mouse model of Down syndrome.J. Neurosci.333953–3966. 10.1523/JNEUROSCI.1203-12.2013
115
McCauleyJ. L.OlsonL. M.DelahantyR.AminT.NurmiE. L.OrganE. L.et al (2004). A linkage disequilibrium map of the 1-Mb 15q12 GABAA receptor subunit cluster and association to autism.Am. J. Med. Genet. B Neuropsychiatr. Genet.131B51–59. 10.1002/ajmg.b.30038
116
Meguro-HorikeM.YasuiD. H.PowellW.SchroederD. I.OshimuraM.LasalleJ. M.et al (2011). Neuron-specific impairment of inter-chromosomal pairing and transcription in a novel model of human 15q-duplication syndrome.Hum. Mol. Genet.203798–3810. 10.1093/hmg/ddr298
117
MiyashiroK. Y.Beckel-MitchenerA.PurkT. P.BeckerK. G.BarretT.LiuL.et al (2003). RNA cargoes associating with FMRP reveal deficits in cellular functioning in Fmr1 null mice.Neuron37417–431. 10.1016/S0896-6273(03)00034-5
118
ModyI.PearceR. A. (2004). Diversity of inhibitory neurotransmission through GABAA receptors.Trends Neurosci.27569–575. 10.1016/j.tins.2004.07.002
119
MohlerH.FritschyJ. M.RudolphU. (2002). A new benzodiazepine pharmacology.J. Pharmacol. Exp. Ther.3002–8. 10.1124/jpet.300.1.2
120
MomosakiS.HosoiR.AbeK.InoueO. (2010). Remarkable selectivity of the in vivo binding of [3H]Ro15-4513 to α5 subtype of benzodiazepine receptor in the living mouse brain.Synapse64928–936. 10.1002/syn.20812
121
MorishimaT.UematsuM.FurukawaT.YanagawaY.FukudaA.YoshidaS. (2010). GABA imaging in brain slices using immobilized enzyme-linked photo analysis.Neurosci. Res.67347–353. 10.1016/j.neures.2010.04.005
122
MortensenM.SmartT. G. (2006). Extrasynaptic αβ subunit GABAA receptors on rat hippocampal pyramidal neurons.J. Physiol.577841–856. 10.1113/jphysiol.2006.117952
123
MunroG.Lopez-GarciaJ. A.Rivera-ArconadaI.ErichsenH. K.NielsenE. O.LarsenJ. S.et al (2008). Comparison of the novel subtype-selective GABAA receptor-positive allosteric modulator NS11394 [3′-[5-(1-hydroxy-1-methyl-ethyl)-benzoimidazol-1-yl]-biphenyl-2-carbonitrile] with diazepam, zolpidem, bretazenil, and gaboxadol in rat models of inflammatory and neuropathic pain.J. Pharmacol. Exp. Ther.327969–981. 10.1124/jpet.108.144568
124
NakanishiK.YamadaJ.TakayamaC.OohiraA.FukudaA. (2007). NKCC1 activity modulates formation of functional inhibitory synapses in cultured neocortical neurons.Synapse61138–149. 10.1002/syn.20352
125
NavarroJ. F.BuronE.Martin-LopezM. (2002). Anxiogenic-like activity of L-655,708, a selective ligand for the benzodiazepine site of GABAA receptors which contain the α-5 subunit, in the elevated plus-maze test.Prog. Neuropsychopharmacol. Biol. Psychiatry261389–1392. 10.1016/S0278-5846(02)00305-6
126
NusserZ.ModyI. (2002). Selective modulation of tonic and phasic inhibitions in dentate gyrus granule cells.J. Neurophysiol.872624–2628.
127
NusserZ.SieghartW.SomogyiP. (1998). Segregation of different GABAA receptors to synaptic and extrasynaptic membranes of cerebellar granule cells.J. Neurosci.181693–1703.
128
NuttD. J.BessonM.WilsonS. J.DawsonG. R.Lingford-HughesA. R. (2007). Blockade of alcohol’s amnestic activity in humans by an α5 subtype benzodiazepine receptor inverse agonist.Neuropharmacology53810–820. 10.1016/j.neuropharm.2007.08.008
129
Olmos-SerranoJ. L.CorbinJ. G.BurnsM. P. (2011). The GABAA receptor agonist THIP ameliorates specific behavioral deficits in the mouse model of fragile X syndrome.Dev. Neurosci.33395–403. 10.1159/000332884
130
Olmos-SerranoJ. L.PaluszkiewiczS. M.MartinB. S.KaufmannW. E.CorbinJ. G.HuntsmanM. M. (2010). Defective GABAergic neurotransmission and pharmacological rescue of neuronal hyperexcitability in the amygdala in a mouse model of fragile X syndrome.J. Neurosci.309929–9938. 10.1523/JNEUROSCI.1714-10.2010
131
OlsenR. W.SieghartW. (2008). International union of pharmacology.LXX. Subtypes of γ-aminobutyric acid A receptors: classification on the basis of subunit composition, pharmacology, and function. Update. Pharmacol. Rev.60243–260. 10.1124/pr.108.00505
132
OwensD. F.BoyceL. H.DavisM. B.KriegsteinA. R. (1996). Excitatory GABA responses in embryonic and neonatal cortical slices demonstrated by gramicidin perforated-patch recordings and calcium imaging.J. Neurosci.166414–6423.
133
OwensD. F.KriegsteinA. R. (2002). Is there more to GABA than synaptic inhibition?Nat. Rev. Neurosci.3715–727. 10.1038/nrn919
134
Perez-CremadesD.HernandezS.Blasco-IbanezJ. M.CrespoC.NacherJ.VareaE. (2010). Alteration of inhibitory circuits in the somatosensory cortex of Ts65Dn mice, a model for Down’s syndrome.J. Neural. Transm.117445–455. 10.1007/s00702-010-0376-9
135
PrenosilG. A.Schneider GasserE. M.RudolphU.KeistR.FritschyJ. M.VogtK. E. (2006). Specific subtypes of GABAA receptors mediate phasic and tonic forms of inhibition in hippocampal pyramidal neurons.J. Neurophysiol.96846–857.
136
RedrobeJ. P.ElsterL.FrederiksenK.BundgaardC.De JongI. E.SmithG. P.et al (2012). Negative modulation of GABAA α5 receptors by RO4938581 attenuates discrete sub-chronic and early postnatal phencyclidine (PCP)-induced cognitive deficits in rats.Psychopharmacology221451–468. 10.1007/s00213-011-2593-9
137
RichardsonB. D.LingL. L.UteshevV. V.CasparyD. M. (2011). Extrasynaptic GABAA receptors and tonic inhibition in rat auditory thalamus.PLoS ONE 6:e16508. 10.1371/journal.pone.0016508
138
RichardsonB. D.LingL. L.UteshevV. V.CasparyD. M. (2013). Reduced GABAA receptor-mediated tonic inhibition in aged rat auditory thalamus.J. Neurosci.331218–1227. 10.1523/JNEUROSCI.3277-12.2013
139
RodeF.JensenD. G.Blackburn-MunroG.BjerrumO. J. (2005). Centrally-mediated antinociceptive actions of GABAA receptor agonists in the rat spared nerve injury model of neuropathic pain.Eur. J. Pharmacol.516131–138. 10.1016/j.ejphar.2005.04.034
140
RodenW. H.PeughL. D.JansenL. A. (2010). Altered GABAA receptor subunit expression and pharmacology in human Angelman syndrome cortex.Neurosci. Lett.483167–172. 10.1016/j.neulet.2010.08.001
141
SaabB. J.MacLeanA. J.KanisekM.ZurekA. A.MartinL. J.RoderJ. C.et al (2010). Short-term memory impairment after isoflurane in mice is prevented by the α5 γ-aminobutyric acid type A receptor inverse agonist L-655,708.Anesthesiology1131061–1071. 10.1097/ALN.0b013e3181f56228
142
SalibaR. S.KretschmannovaK.MossS. J. (2012). Activity-dependent phosphorylation of GABAA receptors regulates receptor insertion and tonic current.EMBO J.312937–2951. 10.1038/emboj.2012.109
143
SallJ. W.StratmannG.LeongJ.McKleroyW.MasonD.ShenoyS.et al (2009). Isoflurane inhibits growth but does not cause cell death in hippocampal neural precursor cells grown in culture.Anesthesiology110826–833. 10.1097/ALN.0b013e31819b62e2
144
SanthakumarV.HancharH. J.WallnerM.OlsenR. W.OtisT. S. (2006). Contributions of the GABAA receptor α6 subunit to phasic and tonic inhibition revealed by a naturally occurring polymorphism in the α6 gene.J. Neurosci.263357–3364. 10.1523/JNEUROSCI.4799-05.2006
145
SarkarJ.WakefieldS.MacKenzieG.MossS. J.MaguireJ. (2011). Neurosteroidogenesis is required for the physiological response to stress: role of neurosteroid-sensitive GABAA receptors.J. Neurosci.3118198–18210. 10.1523/JNEUROSCI.2560-11.2011
146
SatoM.StrykerM. P. (2010). Genomic imprinting of experience-dependent cortical plasticity by the ubiquitin ligase gene Ube3a.Proc. Natl. Acad. Sci. U.S.A.1075611–5616. 10.1073/pnas.1001281107
147
SatomotoM.SatohY.TeruiK.MiyaoH.TakishimaK.ItoM.et al (2009). Neonatal exposure to sevoflurane induces abnormal social behaviors and deficits in fear conditioning in mice.Anesthesiology110628–637. 10.1097/ALN.0b013e3181974fa2
148
SaxenaN. C.MacDonaldR. L. (1996). Properties of putative cerebellar γ-aminobutyric acid A receptor isoforms.Mol. Pharmacol.49567–579.
149
ScimemiA.AnderssonA.HeeromaJ. H.StrandbergJ.RydenhagB.McEvoyA. W.et al (2006). Tonic GABAA receptor-mediated currents in human brain.Eur. J. Neurosci.241157–1160. 10.1111/j.1460-9568.2006.04989.x
150
SemyanovA.WalkerM. C.KullmannD. M. (2003). GABA uptake regulates cortical excitability via cell type-specific tonic inhibition.Nat. Neurosci.6484–490.
151
ShenH.GongQ. H.AokiC.YuanM.RudermanY.DattiloM.et al (2007). Reversal of neurosteroid effects at α4β2δ GABAA receptors triggers anxiety at puberty.Nat. Neurosci.10469–477.
152
SmithS. S.GongQ. H.HsuF. C.MarkowitzR. S.ffrench-MullenJ. M. H.LiX. (1998). GABAA receptor α4 subunit suppression prevents withdrawal properties of an endogenous steroid.Nature392926–930. 10.1038/31948
153
SongI.SavtchenkoL.SemyanovA. (2011). Tonic excitation or inhibition is set by GABAA conductance in hippocampal interneurons.Nat. Commun.2376 10.1038/ncomms1377
154
SongI.VolynskiK.BrennerT.UshkaryovY.WalkerM.SemyanovA. (2013). Different transporter systems regulate extracellular GABA from vesicular and non-vesicular sources.Front. Cell. Neurosci. 7:23. 10.3389/fncel.2013.00023
155
SperkG.SchwarzerC.TsunashimaK.FuchsK.SieghartW. (1997). GABAA receptor subunits in the rat hippocampus I: immunocytochemical distribution of 13 subunits.Neuroscience80987–1000. 10.1016/S0306-4522(97)00146-2
156
StellB. M.BrickleyS. G.TangC. Y.FarrantM.ModyI. (2003). Neuroactive steroids reduce neuronal excitability by selectively enhancing tonic inhibition mediated by δ subunit-containing GABAA receptors.Proc. Natl. Acad. Sci. U.S.A.10014439–14444. 10.1073/pnas.2435457100
157
StratmannG.SallJ. W.MayL. D.BellJ. S.MagnussonK. R.RauV.et al (2009). Isoflurane differentially affects neurogenesis and long-term neurocognitive function in 60-day-old and 7-day-old rats.Anesthesiology110834–848. 10.1097/ALN.0b013e31819c463d
158
TakayamaC.InoueY. (2005). Developmental expression of GABA transporter-1 and 3 during formation of the GABAergic synapses in the mouse cerebellar cortex.Brain Res. Dev. Brain Res.15841–49. 10.1016/j.devbrainres.2005.05.007
159
VardyaI.Hoestgaard-JensenK.Nieto-GonzalezJ. L.DosaZ.BoddumK.HolmM. M.et al (2012). Positive modulation of δ-subunit containing GABAA receptors in mouse neurons.Neuropharmacology63469–479. 10.1016/j.neuropharm.2012.04.023
160
VerkerkA. J.PierettiM.SutcliffeJ. S.FuY. H.KuhlD. P.PizzutiA.et al (1991). Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome.Cell65905–914. 10.1016/0092-8674(91)90397-H
161
VolkD. W.AustinM. C.PierriJ. N.SampsonA. R.LewisD. A. (2000). Decreased glutamic acid decarboxylase67 messenger RNA expression in a subset of prefrontal cortical γ-aminobutyric acid neurons in subjects with schizophrenia.Arch. Gen. Psychiatry57237–245. 10.1001/archpsyc.57.3.237
162
WaffordK. A.Van NielM. B.MaQ. P.HorridgeE.HerdM. B.PedenD. R.et al (2009). Novel compounds selectively enhance δ subunit containing GABAA receptors and increase tonic currents in thalamus.Neuropharmacology56182–189. 10.1016/j.neuropharm.2008.08.004
163
WalshC. A. (1999). Genetic malformations of the human cerebral cortex.Neuron2319–29. 10.1016/S0896-6273(00)80749-7
164
WangD. D.KriegsteinA. R. (2008). GABA regulates excitatory synapse formation in the neocortex via NMDA receptor activation.J. Neurosci.285547–5558. 10.1523/JNEUROSCI.5599-07.2008
165
WangD. S.ZurekA. A.LeckerI.YuJ.AbramianA. M.AvramescuS.et al (2012). Memory deficits induced by inflammation are regulated by α5-subunit-containing GABAA receptors.Cell Rep.2488–496. 10.1016/j.celrep.2012.08.022
166
WangT.KumadaT.MorishimaT.IwataS.KanekoT.YanagawaY.et al (2013). Accumulation of GABAergic neurons, causing a focal ambient GABA gradient, and downregulation of KCC2 are induced during microgyrus formation in a mouse model of polymicrogyria.Cereb. Cortex. 10.1093/cercor/bhs375 [Epub ahead of print].
167
WeeberE. J.JiangY. H.ElgersmaY.VargaA. W.CarrasquilloY.BrownS. E.et al (2003). Derangements of hippocampal calcium/calmodulin-dependent protein kinase II in a mouse model for Angelman mental retardation syndrome.J. Neurosci.232634–2644.
168
WeiW.ZhangN.PengZ.HouserC. R.ModyI. (2003). Perisynaptic localization of δ subunit-containing GABAA receptors and their activation by GABA spillover in the mouse dentate gyrus.J. Neurosci.2310650–10661.
169
WilsonI. A.IkonenS.GallagherM.EichenbaumH.TanilaH. (2005). Age-associated alterations of hippocampal place cells are subregion specific.J. Neurosci.256877–6886. 10.1523/JNEUROSCI.1744-05.2005
170
WisdenW.CopeD.KlausbergerT.HauerB.SinkkonenS. T.TretterV.et al (2002). Ectopic expression of the GABAA receptor α6 subunit in hippocampal pyramidal neurons produces extrasynaptic receptors and an increased tonic inhibition.Neuropharmacology43530–549. 10.1016/S0028-3908(02)00151-X
171
WuY.WangW.RichersonG. B. (2003). Vigabatrin induces tonic inhibition via GABA transporter reversal without increasing vesicular GABA release.J. Neurophysiol.892021–2034. 10.1152/jn.00856.2002
172
YamadaJ.FurukawaT.UenoS.YamamotoS.FukudaA. (2007). Molecular basis for the GABAA receptor-mediated tonic inhibition in rat somatosensory cortex.Cereb. Cortex171782–1787. 10.1093/cercor/bhl087
173
YamadaJ.OkabeA.ToyodaH.KilbW.LuhmannH. J.FukudaA. (2004). Cl- uptake promoting depolarizing GABA actions in immature rat neocortical neurones is mediated by NKCC1.J. Physiol.557829–841. 10.1113/jphysiol.2004.062471
174
YangS.WeinerB. D.ZhangL. S.ChoS. J.BaoS. (2011). Homeostatic plasticity drives tinnitus perception in an animal model.Proc. Natl. Acad. Sci. U.S.A.10814974–14979. 10.1073/pnas.1107998108
175
YeeB. K.HauserJ.DolgovV. V.KeistR.MohlerH.RudolphU.et al (2004). GABA receptors containing the α5 subunit mediate the trace effect in aversive and appetitive conditioning and extinction of conditioned fear.Eur. J. Neurosci.201928–1936. 10.1111/j.1460-9568.2004.03642.x
176
YoonJ. H.MaddockR. J.RokemA.SilverM. A.MinzenbergM. J.RaglandJ. D.et al (2010). GABA concentration is reduced in visual cortex in schizophrenia and correlates with orientation-specific surround suppression.J. Neurosci.303777–3781. 10.1523/JNEUROSCI.6158-09.2010
177
ZornS. H.EnnaS. J. (1985). The effect of mouse spinal cord transection on the antinociceptive response to the γ-aminobutyric acid agonists THIP (4,5,6,7-tetrahydroisoxazolo [5,4-c]pyridine-3-ol) and baclofen.Brain Res.338380–383. 10.1016/0006-8993(85)90173-8
178
ZurekA. A.BridgwaterE. M.OrserB. A. (2012). Inhibition of α5 γ-aminobutyric acid type A receptors restores recognition memory after general anesthesia.Anesth. Analg.114845–855. 10.1213/ANE.0b013e31824720da
Summary
Keywords
GABA, GAT, extrasynaptic, ambient, transporter, tonic inhibition, neurological disease, GABAA receptor
Citation
Egawa K and Fukuda A (2013) Pathophysiological power of improper tonic GABAA conductances in mature and immature models. Front. Neural Circuits 7:170. doi: 10.3389/fncir.2013.00170
Received
02 August 2013
Accepted
28 September 2013
Published
24 October 2013
Volume
7 - 2013
Edited by
Alexey Semyanov, RIKEN Brain Science Institute, Japan
Reviewed by
Vincenzo Crunelli, Cardiff University, UK; Sergei Kirischuk, Universitätsmedizin Mainz, Germany
Copyright
© Egawa and Fukuda.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Atsuo Fukuda, Department of Neurophysiology, Hamamatsu University School of Medicine, 20-1 Handayama 1-chome, Higashi-ku, Hamamatsu, Shizuoka 431-3192, Japan e-mail: axfukuda@hama-med.ac.jp
This article was submitted to the journal Frontiers in Neural Circuits.
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.